Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment-Reference-Cited by-同舟云学术

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

Published:2010-08 Issue:1-3 Volume:121 Page:118-124
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Müller Norbert,Krause Daniela,Dehning Sandra,Musil Richard,Schennach-Wolff Rebecca,Obermeier Michael,Möller Hans-Jürgen,Klauss Volker,Schwarz Markus J.,Riedel Michael

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference41 articles.

1. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial;Akhondzadeh;Depress. Anxiety,2009

2. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial;Akhondzadeh;Schizophr. Res.,2007

3. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia;Ashdown;Mol. Psychiatry,2006

4. The risk for schizophrenia from childhood and adult infections;Brown;Am. J. Psychiatry,2008

5. Serologic evidence of prenatal influenza in the etiology of schizophrenia;Brown;Arch. Gen. Psychiatry,2004

Cited by 216 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alterations in fecal bacteriome virome interplay and microbiota-derived dysfunction in patients with schizophrenia;2024-08-10

2. Circulating microRNA Profiles Identify a Patient Subgroup with High Inflammation and Severe Symptoms in Schizophrenia Experiencing Acute Psychosis;International Journal of Molecular Sciences;2024-04-12

3. Antipsychotic Effects of Celecoxib Add-On Haloperidol in Schizophrenia: A Randomized Double-Blind Placebo-Controlled Clinical Trial;Iranian Journal of Psychiatry and Behavioral Sciences;2024-03-02

4. Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-01

5. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial;Brain, Behavior, and Immunity;2024-01